The companies Atonco (Nantes-Saint Herblain, France) and Ionetix Corporation (Lansing, MI) have signed a partnership agreement to ensure the radioisotope production and supply of the radiopharmaceutical necessary for the success of Atonco’s clinical studies and commercialization in the United States.

Atonco, a radiopharmaceutical company at the clinical stage, aims to demonstrate through its clinical research program the relevance of a breakthrough therapeutic treatment and alpha immunotherapy when targeting superficial bladder cancer.

To read more please visit:

IONETIX and ATONCO Sign a Partnership Agreement to Fight Bladder Cancer

Source: IONETIX